Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Centre Hospitalier Universitaire de Besançon, Besançon, France.
Elsa
E
Curtit
Antoine
A
Thiery-Vuillemin
Thierry
T
Nguyen
Bruno
B
Heyd
Xavier
X
Pivot
Vincent
V
Di Martino
Christophe
C
Borg
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D038524:Diffusion Magnetic Resonance Imaging; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000378:metabolism; D048490:raf Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
C097353:AFP protein, human; D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D000509:alpha-Fetoproteins; D009536:Niacinamide; D000077157:Sorafenib; D048490:raf Kinases